Vifor Pharma Group closed its divestment transaction regarding its finished drug product manufacturing business with facilities in Fribourg, Ettingen (both in Switzerland) and Lisbon (Portugal) to CordenPharma, a full-service Contract Development & Manufacturing Organisation (CDMO) of APIs, Excipients, Drug Products, and associated Packaging services.
The Vifor Pharma Group is a global pharmaceutical company aiming to become the global leader in iron deficiency, nephrology and cardio-renal therapies.
The companies have agreed not to disclose financial terms of the agreement.
Kellerhals Carrard acted as legal advisor to Vifor Pharma on this transaction. The team was led by partner Emanuel Dettwiler (pictured) and comprised senior associate Sophie Holdt, associate Jon Oetiker (all corporate/m&a), and counsels Christine Bassanello (employment) and Philipp d’Hondt (notarial services).